4-[N-[4-(2-(4-Chlorophenyl)ethenyl)phenylcarbonyl]amino]butyric acid | 892861-38-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 4-[N-[4-(2-(4-Chlorophenyl)ethenyl)phenylcarbonyl]amino]butyric acid
• 英文别名: 4-[[4-[(E)-2-(4-chlorophenyl)ethenyl]benzoyl]amino]butanoic acid
• CAS: 892861-38-0
• 化学式: C₁₉H₁₈ClNO₃
• 分子量: 343.81
• InChiKey: RAKBLUFPULCYKL-ONEGZZNKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-[N-[4-(2-(4-Chlorophenyl)ethenyl)phenylcarbonyl]amino]butyric acid 在 盐酸 、 1-羟基苯并三唑一水物 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.83h， 生成 N-Hydroxy-4-[N-[4-(2-(4-chlorophenyl)ethenyl)phenylcarbonyl]amino]butyramide
  参考文献：
  名称：

  Discovery of a new chemical lead for a matrix metalloproteinase inhibitor

  摘要：

  A series of N-benzoyl gamma-aminobutyric hydroxamic acids were synthesized and evaluated as matrix metalloproteinase inhibitors. First, we focused on chemical modification of the N-benzoyl residue. Introduction of electron-rich para-substituents was effective to increase the inhibitory activity. Especially, some of the analogs with relatively more planar N-acyl residues, such as 10 and 11, demonstrated more potent activity. Second, chemical modification of the gamma-aminobutyric hydroxamic acid moiety was carried out to optimize the three-dimensional arrangement of the two pharmacophores (hydroxamic acid and N-acyl residues). Among the tested, the gamma-aminobutyric hydroxamic acid moiety was found to be the best spacer for connecting the above-mentioned two pharmacophores. Synthesis and structure-activity relationships are discussed. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.01.059

文献信息

• AMINOBUTANOIC ACID DERIVATIVES
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1024134A1

  公开（公告）日：2000-08-02

  An aminobutyric acid derivative of the formula (I): (wherein all symbols are as defined in the specification) and salt thereof. salt thereof. The compounds of the formula (I) possess an inhibitory activity on matrix metalloproteinase and are useful for prevention and / or treatment of diseases, for example, rheumatoid diseases, arthrosteitis, unusual bone resorption, osteoporosis, periodontitis, interstitial nephritis, arteriosclerosis, pulmonary emphysema, cirrhosis, cornea injury, metastasis of, invasion of or growth of tumor cells, autoimmune disease (e.g. Crohn's disease, Sjogren's syndrome), disease caused by vascular emigration or infiltration of leukocytes, arterialization, multiple sclerosis, aorta aneurysm, endometriosis.

  式（I）的氨基丁酸衍生物： (其中所有符号如说明书中所定义）及其盐。 式（I）化合物对基质金属蛋白酶具有抑制活性，可用于预防和/或治疗疾病，例如类风湿病、关节炎、异常骨吸收、骨质疏松症、牙周炎、间质性肾炎、动脉硬化、肺气肿、肝硬化、角膜损伤、肿瘤细胞的转移、侵入或生长、自身免疫性疾病（如克罗恩病、Sj.如克罗恩病、Sjogren 综合症）、血管移位或白细胞浸润引起的疾病、动脉化、多发性硬化、主动脉瘤、子宫内膜异位症。
• US6420427B1
  申请人：——

  公开号：US6420427B1

  公开（公告）日：2002-07-16
• Discovery of a new chemical lead for a matrix metalloproteinase inhibitor
  作者：Masahiro Ikura、Shingo Nakatani、Shingo Yamamoto、Hiromu Habashita、Tsuneyuki Sugiura、Kanji Takahashi、Koji Ogawa、Hiroyuki Ohno、Hisao Nakai、Masaaki Toda

  DOI：10.1016/j.bmc.2006.01.059

  日期：2006.6

  A series of N-benzoyl gamma-aminobutyric hydroxamic acids were synthesized and evaluated as matrix metalloproteinase inhibitors. First, we focused on chemical modification of the N-benzoyl residue. Introduction of electron-rich para-substituents was effective to increase the inhibitory activity. Especially, some of the analogs with relatively more planar N-acyl residues, such as 10 and 11, demonstrated more potent activity. Second, chemical modification of the gamma-aminobutyric hydroxamic acid moiety was carried out to optimize the three-dimensional arrangement of the two pharmacophores (hydroxamic acid and N-acyl residues). Among the tested, the gamma-aminobutyric hydroxamic acid moiety was found to be the best spacer for connecting the above-mentioned two pharmacophores. Synthesis and structure-activity relationships are discussed. (c) 2006 Elsevier Ltd. All rights reserved.